Tronox (TROX) Q1 2026 Earnings Call Transcript

Tronox reported Q1 revenue of $760 million, up 3% year over year, but adjusted EBITDA fell 45% to $62 million and the company posted a $103 million net loss with $135 million of free cash flow use. Management expects Q2 adjusted EBITDA of $65 million to $85 million and positive free cash flow for the quarter and full year, supported by TiO2 and zircon price increases, though margin pressure remains from sharply higher sulfur and raw material costs tied to the Middle East conflict. The call also highlighted restructuring charges from Botlek and Fuzhou closures, $3.2 billion of net debt, and ongoing liquidity management via an upsized AR securitization facility.

Analysis

The market is underestimating how much of this setup is a relative-value story inside TiO2 rather than a simple cyclical recovery. Tronox’s chloride-heavy footprint gives it a temporary margin and reliability advantage just as sulfate producers face a cost shock they cannot fully pass through, which should pressure weaker Chinese and European marginal supply before it meaningfully benefits demand elasticity. That creates a second-order effect: customers that value continuity will lock in longer-dated chloride supply, while the spot market for lower-grade sulfate pigment becomes more dislocated and less liquid.

The bigger near-term swing factor is not demand, but the speed of price realization versus the lag on surcharges and contract resets. If sulfur stays elevated through 2Q, Tronox can still miss the optics on margin because input inflation hits immediately while monetization trails into 3Q; that means reported EBITDA can look softer than underlying pricing power. The important tell will be inventory and order-book conversion: if they truly cannot fill orders, this is a volume-constrained upside revision story, not just a price story.

The balance sheet is the real hidden risk. Liquidity is adequate, but leverage remains high enough that any disappointment in working capital release or a reversal in the sulfur shock could quickly reframe the equity as a refinancings-and-execution name rather than a commodity recovery trade. Conversely, the current environment could accelerate competitive exits among smaller chlorination and sulfate players, which would expand Tronox’s moat over the next 6-18 months.

The contrarian read is that the stock may be closer to inflecting than consensus expects, but for reasons different from the headline narrative. The biggest earnings lever may come from mix and capacity discipline in the second half, not simply from macro price beta, so the trade works best if investors are willing to own a lagged, cash-flow re-rating rather than chase a one-quarter beat.

Key Decisions for Investors

• Long TROX into the next 1-2 quarters on a delayed-pass-through thesis; target a 20-30% re-rating if 3Q pricing flows through and working capital converts as guided. Exit/trim if sulfur normalizes faster than expected or if 2Q cash burn reaccelerates.
• Pair trade: long TROX / short HUN for 3-6 months. The relative thesis is that Tronox has a stronger supply-side tailwind from trade defense and chloride exposure, while HUN has less direct benefit from the sulfur shock. Use a 1:1 dollar-neutral structure; stop if TROX fails to reaccelerate EBITDA in 2H.
• For more convex exposure, buy TROX 6-9 month calls or call spreads rather than stock. This captures upside from a 2H margin inflection while capping risk around balance-sheet or working-capital disappointment.
• Watch for confirmation in European and U.K. antidumping actions over the next 30-90 days; if provisional duties appear, add to TROX on the first pullback because trade protection could tighten supply faster than pricing models imply.
• Avoid chasing the move if you need near-term earnings certainty; this is a better trade for investors with a 2H 2026 horizon, since 2Q margins may still look noisy despite improving underlying economics.